Nimotuzumab with radiation for older women with cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies whether adding nimotuzumab (an antibody medicine) to radiation (IMRT) can improve outcomes for older adults with cervical squamous cell cancer. It’s for people who cannot tolerate or choose not to have chemotherapy, and who have eligible health test results for safe treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 65 or older.
- Have confirmed cervical squamous cell cancer that is stage IB3 through IVA.
- Have at least one measurable tumor area for tracking response.
- Be unable to take chemotherapy or choose not to take it.
- Have labs and organ health that are safe for treatment (blood counts, liver, and kidneys).
- Have an ECOG activity score of 0 to 2 and life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called nimotuzumab combined with standard chemotherapy and radiation for patients with esophageal cancer. It may help improve treatment effectiveness for those whose cancer has not spread to other parts of the body.
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
This trial tests adding nimotuzumab (a targeted antibody) to standard chemoradiation for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This study tests whether adding the drug nimotuzumab to standard chemoradiotherapy (radiation plus chemo) and then continuing maintenance therapy works better for locally advanced cervical cancer (stages IB3 to IVA) than chemoradiotherapy alone.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) plus radiation for women whose cervical cancer has come back or spread to a few places in the body. The goal is to see if this treatment can shrink tumors and help patients live longer.
This trial tests adding nimotuzumab, a targeted therapy, to standard chemoradiation for elderly patients with esophageal squamous cell cancer. It aims to see if the combination improves outcomes.
Hear when a new Cervical Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.